LAS VEGAS (May 21, 2019) - New study results validate the effectiveness of the Saranas™ Early Bird™ Bleed Monitoring System to sense bleeding events during endovascular related procedures by using sensors to detect relative changes in tissue bioimpedance. The study enrolled 60 patients from five sites who underwent an endovascular procedure and detected bleeding in more than half of patients. The results of this study are being presented as late-breaking clinical research on Wednesday, May 22, 2019 at the Society for Cardiovascular Angiography Interventions (SCAI) 2019 Scientific Sessions.
One in five patients experience a bleeding complication during large-bore endovascular procedures such as transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair and percutaneous left ventricular assist device implant. This complication is associated with significant increase in risk of mortality, length of hospital stay and healthcare costs, according to a 2017 Journal of the American Medical Association study. The Early Bird™ device is designed to be integrated during endovascular procedures and inserted in a vessel in anticipation of a bleed. The technology was invented at the Texas Heart Institute in Houston, TX.
From August 2018 to December 2018, a total of 60 patients (mean age 76 years, 42 percent females) from five U.S. sites were enrolled and underwent an endovascular procedure (TAVR 67 percent; percutaneous coronary intervention (PCI) 13 percent; Impella 8 percent; balloon aortic valvuloplasty seven percent; transcatheter mitral valve replacement (TMVR) two percent, endovascular aneurysm repair (EVAR) two percent and MitraClip two percent). The Early Bird was used during and after endovascular procedures, either as a venous or arterial access sheath. In the case of bleeding, the device has a sensor which detects the onset of bleeding and characterizes bleed progression into I, II, and III levels. The primary endpoint was the level of agreement in bleeding detection between the Saranas Early Bird™ and post-procedural computerized tomography.
Early Bird™ detected bleeding in 63 percent of patients, with 33 percent of those patients at bleeding level I, 23 percent at bleeding level II, and seven percent at bleeding level III. No device-related complications were reported.
"This is the first time we're seeing how this device could help in a real-world patient setting, and we were very encouraged by the results. Right now, patients have a risk of vessel injury when undergoing endovascular procedures where the femoral artery or vein is used for vascular access," said Philippe Genereux, MD, principal investigator, cardiologist and physician at Morristown Medical Center in Morristown, NJ. "This technology allows us to detect bleeding in real-time which means we can take action quickly and improve the outcomes of the procedure and recovery for the patient."
In March, the Early Bird™ device was granted de novo classification by the U.S. Food and Drug Administration (FDA) and plans to conduct a controlled roll out to institutions interested in having bleed management as part of their standard of care.
"As the first and only device on the market for early bleed detection, we have the potential to significantly reduce the severity of bleeding complications and resulting costs, while improving clinical outcomes in patients undergoing endovascular procedures, "said Zaffer Syed, chief executive officer at Saranas.
The authors note plans to continue research of the device with controlled studies at institutions who have specific interest in bleed management. Post approval study and practices will evolve as the authors continue to evaluate and collect data on the device.
"Featured Clinical Research, Part II: First-in-Human Study of the Saranas Early Bird™ Bleed Monitoring System for the Detection of Endovascular Procedure Related Bleeding Events" [May 22, 2019, 11:20 - 11:30 a.m. PDT, Belmont Ballroom 4]
The Society for Cardiovascular Angiography and Interventions is a 5,000-member professional organization representing invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care.
For more information about the SCAI 2019 Scientific Sessions, visit http://www.